Vasculitis & polymyalgia rheumatica
Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease
Main finding · Incidence of intestinal BDResult — go to the resultAdjusted hazard ratio 2.48 95% CI 1.38–4.47Authors' conclusion
This study demonstrates a significant association between PPI use and increased incidence of intestinal BD in patients with BD.
Study context
- Population
- Patients with Behçet disease (BD) diagnosed between April 2005 and November 2023, The University of Tokyo Hospitalmean follow-up 12 years
- Participants
- 194 patients
- Exposure
- Proton pump inhibitor (PPI) users vs nonusers
- Outcome
- Incidence of intestinal BD
Methodological detailssingle-centre, Cox models, Kaplan-Meier analyses, propensity score-matched cohort
- Single-centre
- Cox models
- Kaplan-Meier analyses
- Propensity score-matched cohort
Main finding
As reported in the abstract
Adjusted hazard ratio
2.48
95% CI 1.38–4.47
P = 0.002
PPI usersvs Nonusers
aHR 2.48 (95% CI 1.38–4.47); P = 0.002
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Cumulative incidence of intestinal BDMarkedly elevated in PPI users | log-rank P < 0.001 |
Intestinal BD in the whole cohort · mean follow-up of 12 years
- Developed intestinal BD
- 25.3%
Original publication
Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease. J Rheumatol. Published 1 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →